Galapagos制药 GLPG 深 沪
等待开盘 12-15 09:30:00 美东时间
31.69
-0.880
-2.70%
华盛通- 最 高32.495
- 今 开32.25
- 成交量 6.27万股
- 最 低 31.66
- 昨 收 32.57
- 总市值 20.88亿
- 52周最高 37.78
- 市盈率 静 26.16
- 换手率 0.00%
- 52周最低 22.36
- 委 比 50.82%
- 总股本 6589.71万
- 历史最高 274.03
- 量 比 0.74
- 振 幅 2.56%
- 历史最低 13.023
- 每 手 1
- 风险率 3.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Galapagos Shares Updated ATALANTA-1 Results At ASH 2025 Showing High Response Rates And Durable Responses With GLPG5101 In MCL
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day
12-08 15:42
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
RBC Capital Maintains Sector Perform on Galapagos, Raises Price Target to $32
RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and raises the price target from $28 to $32.
11-08 03:04
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Galapagos NV Strengthens Board with Strategic Appointments
Galapagos ( ($GLPG) ) has provided an announcement. On October 30, 2025, Galapa...
10-31 04:59
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Leerink Partners Upgrades Galapagos to Outperform, Raises Price Target to $40
Leerink Partners analyst Faisal Khurshid upgrades Galapagos (NASDAQ:GLPG) from Market Perform to Outperform and raises the price target from $29 to $40.
10-22 04:43
Galapagos falls after plans to shut down cell therapy unit
Galapagos (NASDAQ:GLPG) ADRs dropped ~13% in the premarket on Tuesday after the Belgian biotech announced plans to wind down its cell therapy business, impacting roughly 365 employees in Europe, the U...
10-21 19:40
